Ocular Hypertension News and Research

RSS
Tips on making a smooth transition to optimal eye care

Tips on making a smooth transition to optimal eye care

Trifocal lenses: the best chance of true spectacle independence?

Trifocal lenses: the best chance of true spectacle independence?

Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

New, regenerative medicine approach developed to remove congenital cataracts in infants

New, regenerative medicine approach developed to remove congenital cataracts in infants

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Glial cells promise as new target to modulate retinal synaptic plasticity after retinal injury

Glial cells promise as new target to modulate retinal synaptic plasticity after retinal injury

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Clues of "silent thief of sight”: Glaucoma

Clues of "silent thief of sight”: Glaucoma

Prostaglandin analogues cause droopy eyelids, new study finds

Prostaglandin analogues cause droopy eyelids, new study finds

Fixed-dose combination of drugs effectively lowers IOP

Fixed-dose combination of drugs effectively lowers IOP

Amakem backs new Chair of Ophthalmology Translational Research at KU Leuven

Amakem backs new Chair of Ophthalmology Translational Research at KU Leuven

Sucampo launches RESCULA Eye Drops in the U.S.

Sucampo launches RESCULA Eye Drops in the U.S.

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Glaucoma likely to end in visual impairment

Glaucoma likely to end in visual impairment

Only assess glaucoma drug efficacy after multiple testing

Only assess glaucoma drug efficacy after multiple testing

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension